Literature DB >> 14583185

Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation.

Masahiro Okouchi1, Naotsuka Okayama, Hitoshi Omi, Kenro Imaeda, Manabu Shimizu, Tatsuya Fukutomi, Makoto Itoh.   

Abstract

BACKGROUND AND AIMS: There is growing evidence that hyperinsulinemia is linked to the development of atherosclerosis in patients with diabetes. We demonstrated previously that high insulin exacerbates neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule (ICAM)-1 expression through activation of protein kinase C (PKC) and mitogen-activated protein (MAP) kinase. Though 3-hydroxymethyl-3-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been employed as therapeutic agents in the treatment of dyslipidemia, which is frequently accompanied by diabetes mellitus; it is not known whether statins protect against leukocyte-endothelial interactions, especially in hyperinsulinemia. In this study, we determined which statin(s) could protect against endothelial reactions to high insulin.
METHODS: Studies of adhesion between neutrophils from healthy volunteers and human umbilical vein endothelial cells incubated in regular insulin-rich medium with or without statins were performed. Adhered neutrophils were quantified by measuring their myeloperoxidase (MPO) activities, and endothelial expression of ICAM-1 was examined using an enzyme immunoassay.
RESULTS: Both the increased neutrophil-endothelial cell adhesion and ICAM-1 expression caused by high insulin (100 microU/ml) for 48 h were significantly attenuated by pretreatment with cerivastatin (0.01 microM), but not by fluvastatin (0.5 microM) or pravastatin (0.05 microM). These protective actions of cerivastatin were attenuated by a key intermediate in the cholesterol biosynthesis pathway, mevalonate (400 microM). In addition, cerivastatin attenuated both neutrophil-endothelial cell adhesion and endothelial ICAM-1 expression enhanced by a MAP kinase activator, anisomycin (1 microM) but not by a PKC activator, PMA (10 nM).
CONCLUSIONS: These results suggest that through inhibiting MAP kinase but not PKC activation therapy with cerivastatin would be promising strategy for inhibiting neutrophil-endothelial cell adhesion and endothelial ICAM-1 expression enhanced by high insulin, which is closely correlated with atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583185     DOI: 10.1016/s1056-8727(02)00245-3

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  5 in total

1.  Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.

Authors:  Carmem Patrícia Barbosa; Alessandra Milene Ritter; Lorena Gimenez da Silva; Renata Grespan; Roberto Kenji Nakamura Cuman; Luzmarina Hernandes; Ciomar Aparecida Bersani-Amado
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

2.  Simvastatin protects against cholestasis-induced liver injury.

Authors:  S Dold; M W Laschke; S Lavasani; M D Menger; B Jeppsson; H Thorlacius
Journal:  Br J Pharmacol       Date:  2008-01-13       Impact factor: 8.739

Review 3.  Statins and the vascular endothelial inflammatory response.

Authors:  John Greenwood; Justin C Mason
Journal:  Trends Immunol       Date:  2007-01-02       Impact factor: 16.687

4.  Effect of statins on endothelial function in patients with acute coronary syndrome: a prospective study using adhesion molecules and flow-mediated dilatation.

Authors:  Ibrahim Altun; Fahrettin Oz; Selda Can Arkaya; Ilknur Altun; Ahmet Kaya Bilge; Berrin Umman; Umit Mutlu Turkoglu
Journal:  J Clin Med Res       Date:  2014-07-28

5.  Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia.

Authors:  Angela R Boyd; Cecilia A Hinojosa; Perla J Rodriguez; Carlos J Orihuela
Journal:  BMC Microbiol       Date:  2012-05-15       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.